4//SEC Filing
KARABELAS ARGERIS N 4
Accession 0001562180-24-006015
CIK 0001590877other
Filed
Aug 4, 8:00 PM ET
Accepted
Aug 5, 6:39 PM ET
Size
16.7 KB
Accession
0001562180-24-006015
Insider Transaction Report
Form 4
REGENXBIO Inc.RGNX
KARABELAS ARGERIS N
Director
Transactions
- Exercise/Conversion
Common Stock
2024-08-01$3.76/sh+10,000$37,600→ 21,286 total - Sale
Common Stock
2024-08-01$14.59/sh−400$5,834→ 11,386 total - Sale
Common Stock
2024-08-01$13.45/sh−9,600$129,120→ 11,786 total - Sale
Common Stock
2024-08-01$15.00/sh−100$1,500→ 11,286 total - Exercise/Conversion
Stock Options (Right to Buy)
2024-08-01−10,000→ 20,000 totalExercise: $3.76Exp: 2025-05-19→ Common Stock (10,000 underlying) - Exercise/Conversion
Common Stock
2024-08-01$12.74/sh+100$1,274→ 21,386 total - Exercise/Conversion
Stock Options (Right to Buy)
2024-08-01−100→ 1,400 totalExercise: $12.74Exp: 2026-06-01→ Common Stock (100 underlying)
Footnotes (5)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan.
- [F2]This transaction was executed in multiple trades at prices ranging from $13.20 to $14.05. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F3]This transaction was executed in multiple trades at prices ranging from $14.44 to $14.65. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F4]The previously granted option, representing a right to purchase a total of 12,500 shares, became exercisable as follows: the option vested in 12 equal monthly installments following June 1, 2016.
- [F5]The previously granted option, representing a right to purchase a total of 40,000 shares, became exercisable as follows: 25% of the shares subject to the option vested on May 19, 2015, and the balance vested equal installments over the next 24 months.
Documents
Issuer
REGENXBIO Inc.
CIK 0001590877
Entity typeother
Related Parties
1- filerCIK 0001191229
Filing Metadata
- Form type
- 4
- Filed
- Aug 4, 8:00 PM ET
- Accepted
- Aug 5, 6:39 PM ET
- Size
- 16.7 KB